### Live Learner Notification

#### **Med Learning Group A 3D View: Addressing the Most Common Cancer: The Pathology, Epidemiology, and Treatment Options of Advanced and Metastatic BCC**

**May 6, 2021**

**Online  
  
Acknowledgement of Financial Commercial Support**

Regeneron

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Accreditation Statement**

A picture containing drawing

Description automatically generated

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Pharmacists and Pharmacy Technicians**

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

UAN(s): JA4008163-9999-21-074-L04-P / JA4008163-9999-21-074-L04-T  
**NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

###### Objectives - After Attending This Program You Should Be Able To

1. Discuss the pathogenic drivers of BCC including cellular signaling pathways and immune dysfunction.
2. Review the utility of Mohs micrographic surgery in the evaluation and therapeutic intervention in BCC.
3. Describe systemic therapeutic approaches in the treatment of locally advanced and metastatic BCC.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5). All individuals in a position to control the content of CE are listed below:

|  |  |
| --- | --- |
| **Name** | **Relationship: Commercial Interest** |
| Anna Bar | Consulting Fees: Regeneron Pharmaceuticals; Research Funding: Castle, Mavis, Pelle Pharm |
| Felecia Beachum | NA |
| Chris Drury | NA |
| Matthew Frese | NA |
| Christina Gallo | NA |
| Brianna Hanson | NA |
| Justin Leitenberger | NA |
| Scott McGee-Plys | NA |
| Lauren Welch | NA |

**How to Get Your Certificate**

1. Go to <http://mlg.cmecertificateonline.com>

#### Click on**“5.6.21 A 3D View: Addressing the Most Common Cancer: The Pathology, Epidemiology, and Treatment Options of Advanced and Metastatic BCC**” link.

1. Complete the post-test, click the provided link to go to the online evaluation site.
2. Evaluate the meeting, click the provided link to open your credit certificate.
3. Print/save all pages of your certificate for your records.

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)